Literature DB >> 34204581

Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson's Disease.

Antonella Cardinale1,2, Valeria Calabrese1,3, Antonio de Iure1, Barbara Picconi1,4.   

Abstract

Parkinson's disease (PD) is considered the most common disorder of synucleinopathy, which is characterised by intracellular inclusions of aggregated and misfolded α-synuclein (α-syn) protein in various brain regions, and the loss of dopaminergic neurons. During the early prodromal phase of PD, synaptic alterations happen before cell death, which is linked to the synaptic accumulation of toxic α-syn specifically in the presynaptic terminals, affecting neurotransmitter release. The oligomers and protofibrils of α-syn are the most toxic species, and their overexpression impairs the distribution and activation of synaptic proteins, such as the SNARE complex, preventing neurotransmitter exocytosis and neuronal synaptic communication. In the last few years, the role of the immune system in PD has been increasingly considered. Microglial and astrocyte activation, the gene expression of proinflammatory factors, and the infiltration of immune cells from the periphery to the central nervous system (CNS) represent the main features of the inflammatory response. One of the actors of these processes is α-syn accumulation. In light of this, here, we provide a systematic review of PD-related α-syn and inflammation inter-players.

Entities:  

Keywords:  dopamine; immune system; neuroinflammation; synaptopathy; α-synuclein

Year:  2021        PMID: 34204581     DOI: 10.3390/ijms22126517

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  7 in total

Review 1.  Astrocytes in Neurodegeneration: Inspiration From Genetics.

Authors:  Jingxuan Huang; Chunyu Li; Huifang Shang
Journal:  Front Neurosci       Date:  2022-06-24       Impact factor: 5.152

2.  Knockdown of small nucleolar RNA host gene 10 (SNHG10) alleviates the injury of human neuroblastoma cells via the miR-1277-5p/insulin substrate receptor 2 axis.

Authors:  Zhaoming Sun; Lixiang Song; Jiazhen Li
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

Review 3.  Neuroglial Senescence, α-Synucleinopathy, and the Therapeutic Potential of Senolytics in Parkinson's Disease.

Authors:  Sean J Miller; Cameron E Campbell; Helen A Jimenez-Corea; Guan-Hui Wu; Robert Logan
Journal:  Front Neurosci       Date:  2022-04-19       Impact factor: 5.152

4.  The intricate debate on neurodegeneration and neuroinflammation in Parkinson's disease: which came first?

Authors:  Antonella Cardinale; Valeria Calabrese
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

Review 5.  Oligomeropathies, inflammation and prion protein binding.

Authors:  Gianluigi Forloni; Pietro La Vitola; Claudia Balducci
Journal:  Front Neurosci       Date:  2022-08-23       Impact factor: 5.152

Review 6.  The Effect of Aggregated Alpha Synuclein on Synaptic and Axonal Proteins in Parkinson's Disease-A Systematic Review.

Authors:  Jennifer Murphy; Declan P McKernan
Journal:  Biomolecules       Date:  2022-08-29

Review 7.  Neuroprotection and Disease Modification by Astrocytes and Microglia in Parkinson Disease.

Authors:  Shinichi Takahashi; Kyoko Mashima
Journal:  Antioxidants (Basel)       Date:  2022-01-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.